Chimeric Enzyme for Simultaneous mRNA Transcription and Capping
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current expression systems for eukaryotic cells are inadequate for efficient protein and RNA production, particularly in terms of cytotoxicity and translatability, and existing methods to enhance capping of transcripts have shown limited success.
Innovation Solution
Development of monomeric or oligomeric chimeric enzymes comprising catalytic domains of capping enzymes and a RNA-binding domain of a protein-RNA tethering system, which specifically bind to a specific RNA sequence or structure, to enhance the capping rate of mRNAs produced by RNA polymerase.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If existing expression systems are used for eukaryotic cells, then protein and RNA production can be achieved, but cytotoxicity occurs and translatability is insufficient
Solution Approach 1:
The patent combines RNA polymerase and capping enzyme into a single chimeric enzyme system, allowing transcription and capping to occur simultaneously in the cytoplasm. This integration eliminates the need for nuclear transcription machinery, reducing cytotoxicity while maintaining high productivity for protein and RNA production
2Reliability
If existing methods to enhance capping of transcripts are used, then some improvement in capping efficiency is achieved, but the success is limited
Solution Approach 1:
The chimeric enzyme merges RNA polymerase with capping enzyme activities, enabling simultaneous transcription and capping. This ensures every nascent transcript receives a cap structure immediately, achieving near 100% capping efficiency while maintaining high transcriptional productivity
Solution Approach 2:
The capping enzyme component of the chimeric enzyme performs capping action on nascent transcripts during the transcription process itself, before the transcripts are fully synthesized and released. This preliminary capping ensures high efficiency and immediate protection of the transcripts
3Adaptability or versatility
If RNA polymerase II and associated factors are used for transcription, then endogenous transcription machinery is utilized, but the system complexity increases and efficiency decreases
Solution Approach 1:
The patent extracts the essential transcription function from the complex endogenous RNA polymerase II system and combines it with capping enzyme activity in a simplified chimeric enzyme. This extracted system operates independently in the cytoplasm without requiring nuclear transcription factors, reducing overall system complexity
4Reliability
If capping is performed separately from transcription, then the capping process can be optimized, but the overall efficiency and translatability are reduced
Solution Approach 1:
The chimeric enzyme merges transcription and capping functions into a single molecular complex, allowing both processes to occur simultaneously. This ensures that capping quality is maintained while maximizing throughput, as every transcript is capped during its synthesis without requiring separate processing steps
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Significantly increases the capping rate of specific mRNAs, improving mRNA stability and translation efficiency, and is suitable for large-scale protein production without cytotoxicity.
Implementation Method 1
a RNA-binding domain of a protein-RNA tethering system, which specifically bind to a specific RNA sequence or structure
Implementation Method 2
The catalytic domains of capping enzymes... to enhance the capping rate of mRNAs produced by RNA polymerase
Data Source
AI summary
The present invention relates to a chimeric enzyme comprising or consisting of at least one catalytic domain of a capping enzyme and at least one RNA-binding domain of a protein-RNA tethering system as well as its application for the production of an RNA molecule with a 5′-terminal cap.